The ANGEL-MS extension study will offer the 260 patients enrolled in the on-going Phase IIb CHANGE-MS study the opportunity to continue their treatment for an additional two years and will provide additional efficacy and ...
Therapeutic candidate GNbAC1 is first to target potential primary cause of MS Over 130 of 260 patients enrolled Clinical trial design presented during ECTRIMS Congress Primary data read-out confirmed in 4Q20 ...
GeNeuro Successfully Completes Phase 2a Clinical Study with Novel Approach to Treat Multiple Sclerosis First in Class GNbAC1 mAb Targets Human Endogenous RetroVirus Geneva, Switzerland and Lyon / Archamps, France - ...
Geneva, Switzerland and Archamps, France, September 9, 2013 – Genkyotex, the leading developer of NOX enzyme inhibitors, announced today that the U.S. Food and Drug Administration has approved the company’s Investigation ...
GeNeuro SA announces today the successful completion of its phase I clinical study with GNbAC1, a humanized monoclonal antibody targeting a human endogenous retrovirus, to treat multiple sclerosis. The randomized, doub ...
GeNeuro responsible for development of GNbAC1 till completion of Phase IIb in Multiple Sclerosis, receiving $47M from Servier, after which Servier can exercise licensing option in all markets excluding the USA and Japan. ...
